Severe tumefactive rebound of multiple sclerosis following fingolimod cessation.
Department of Neurology, Salford Royal NHS Foundation Trust, Salford, UK Pennine Acute Hospitals NHS Trust, Manchester, UK.
Sharfaraz
S
Salam
Department of Neurology, Salford Royal NHS Foundation Trust, Salford, UK.
Tatiana
T
Mihalova
Department of Radiology, Salford Royal NHS Foundation Trust, Salford, UK.
Rekha
R
Siripurapu
D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging; D005260:Female; D000068876:Fingolimod Hydrochloride / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D009271:Naltrexone / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000627:therapeutic use; D012008:Recurrence; D028761:Withholding Treatment
D007166:Immunosuppressive Agents; D009292:Narcotic Antagonists; D009271:Naltrexone; D000068876:Fingolimod Hydrochloride